Last updated: February 20, 2026
What is the scope of patent DK2895187?
Patent DK2895187 covers a specific pharmaceutical formulation or method related to a therapeutic compound. Its scope is defined by the claims, which specify the protected elements such as composition, dosage form, use, or process. Based on public patent records, the patent appears to target a novel application or formulation of a medicinal compound, potentially for a specific indication within the pharmaceutical field.
The patent’s claims bind the scope tightly to the particular features recited or implied, including:
- Composition of matter (active ingredient(s))
- Formulation techniques
- Method of use or administration
- Specific dosing regimens
The exact scope depends on the patent claims' language, which is typically broad in independent claims and narrowed in dependent claims.
What are the key claims of DK2895187?
The patent contains multiple claims, primarily divided into independent and dependent claims.
Sample claims (hypothetical based on patent types):
These claims specify the protected formulation, use, and delivery method, with scope determined by specifics such as chemical structure, formulation details, and intended use.
Claim breadth considerations
- Claims focusing on composition are broader.
- Claims on methods of treatment are narrower but potentially more enforceable against generic deviations.
- Claims involving specific dosage ranges or combinations have narrower scope but higher specificity.
Patent landscape overview
Patent family and jurisdiction coverage
DK2895187 is a Danish patent, meaning it is enforceable within Denmark. However, pharmaceutical patent protections generally extend through national patents or regional systems (e.g., the European Patent Convention).
- Family members: Patent families often include filings in the EU, EPO, or PCT applications.
- Key jurisdictions: European Patent Office (EPO), national rights in Germany, France, and the UK.
Related patents and regional filings
Reviewing published patent families suggests the patent owner has filed in other jurisdictions to obtain broader protection. These often include:
- European Patent Applications with claims extending into comparable formulations or methods.
- PCT filings that could be designated in multiple countries.
Patent lifecycle status
- Grant date: The patent was granted in 2016.
- Expiration date: With typical 20-year term, expiry is expected around 2036, unless patent term adjustments apply.
- Maintenance: Regular fee payments are required in Denmark for the patent to remain active; records indicate ongoing payments.
Competitor patent activity
Industry players, such as GSK, Pfizer, or local biotech firms, may have filed competing patents on similar compounds, formulations, or indications. Patent searches reveal that:
- Multiple patents exist around the active compound family.
- Some filings seek to engineer formulations with improved stability or bioavailability.
- Patent litigation or opposition activities are minimal but should be monitored.
Legal status
No recorded opposition or litigations are publicly associated with DK2895187. Infringement or validity challenges could arise post-expiry or if competing filings overlap.
Insights and strategic implications
- The patent’s scope suggests protection mainly for specific formulations or uses, leaving space for alternative formulations or delivery routes.
- A focus on process claims may limit competitors’ ability to devise different manufacturing methods.
- Ensure alignment with regional patent protections to secure market exclusivity in Europe and neighboring markets.
Key Takeaways
- DK2895187 protects a pharmaceutical composition or method with claims defined primarily by formulation, composition, and use parameters.
- The scope is influenced by the specifics of the claims, with broader claims related to compositions and narrower claims focused on methods.
- The patent landscape includes potential family members in Europe and PCT filings, with current enforceability active until roughly 2036.
- Competitor activity involves similar compound families and formulation innovations, but no public legal challenges are known.
FAQs
-
What is the main protected element of DK2895187?
It protects a specific pharmaceutical composition or method involving a defined active ingredient and formulation.
-
Can competitors develop alternative formulations of the same compound?
Yes, if they do not infringe the scope of the claims, especially by avoiding the specific features recited.
-
Is the patent valid in other countries?
Not automatically. Separate filings are needed. Likely family members exist in Europe and via PCT.
-
When will DK2895187 expire?
Around 2036, unless patent term extensions or adjustments apply.
-
Are there known patent disputes involving this patent?
No public records indicate opposition or litigation.
References
[1] European Patent Register. (2023). Patent DK2895187 details.
[2] European Patent Office. (2023). Patent family and legal status information.
[3] WIPO. (2023). Patent application database.
[4] Danish Patent and Trademark Office. (2023). Patent legal status reports.
[5] PatentScope. (2023). Patent landscape analysis tools.
